Skip to main content
OpenTrials
Completed

NCT Number: NCT05842096

Subclinical Hypothyroidism and Chronic Inflammation in PCOS

Chronic inflammation in polycystic ovary syndrome (PCOS) may be the result of dysregulation of cytokine production (due to insulin resistance, excess visceral fat and hyperandrogenemia), i.e., overproduction of pro-inflammatory factors (e.g. TNF, IL-1, IL-6) in relation to anti-inflammatory ones (IL-10). This condition may be an important link between obesity and insulin resistance, which is crucial in the etiopathogenesis of the syndrome. However, it is not known whether it results from the tendency to accumulate adipose tissue or is a feature of the syndrome itself. Concomitant endocrinopathies, i.e. obesity, dyslipidemia, insulin resistance, diabetes and thyroid diseases, may additionally influence the activity of chronic inflammation. There is no data indicating the relationship between chronic inflammation and PCOS phenotypes, the severity of metabolic disorders, ovarian reserve and the influence of thyroid function on its activity in PCOS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries Adnexal Diseases Cysts Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Hypothalamic-Pituitary-Gonadal Axis Dysfunction Neoplasms Ovarian Cysts Ovarian Diseases Polycystic Ovary Syndrome Subclinical hypothyroïdism Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Jagiellonian University Medical College, Department of Gynecology and Obstetrics

Krakow, 31-501, Poland

About this study

The aim of the study is:

i) to assess and compare serum concentrations of selected inflammatory markers (leucocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha) in women with different phenotypes PCOS and hypothalamic-pituitary-ovarian axis dysfunction (HPOD) (control), ii) to evaluate the impact of subclinical hypothyroidism (defined as TSH>2.5 uIU/ml, fT3 3,1-6,80 pmol/l, fT4 12,0-22,0 pmol/l), with the presence and absence of circulating antithyroid antibodies (a-TPO and a-TG), on the balance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes, iii) to assess the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices, expressed as FSH and AMH concentrations.

The study population will be characterized in terms of demographic (age, BMI), gynecological (age of first and last menstrual period, cycle length, history of reproductive organ surgeries, ultrasound measurements of endometrial width, ovarian volume) and obstetrics (pregnancies, childbirth, miscarriages) data. PCOS syndrome (and its phenotypes) will be recognized by the Rotterdam criteria. HPOD will be diagnosed according to WHO criteria. During hospitalization, blood samples will be collected for scheduled analyzes (30 ml of blood in total).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18-45 years,
  • cycle length <21 days or > 35 days,
  • unsuccessful attempts to conceive for at least 12 months of regular intercourse with sonographically confirmed anovulation with excluded male, tubal and uterine infertility factors.

Exclusion criteria

  • absence of at least one ovary,
  • previously diagnosed thyroid disease

Treatment and study plan

Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms

Diagnostic Test

A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study

Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms

Diagnostic Test

A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms

Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices

Diagnostic Test

A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms

Primary outcomes

  1. Values of inflammation parameters - leukocytosis in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of leukocyte count (n/µL) in peripheral blood in both study arms

  2. Values of inflammation parameters - CRP in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of concentrations of CRP (mg/l) in peripheral blood in both study arms

  3. Values of inflammation parameters - procalcitonine in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of concentrations of procalcitonin (μg/l) in peripheral blood in both study arms

  4. Values of inflammation parameters - fibrinogen in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of concentrations of procalcitonin fibrinogen (g/l) in peripheral blood in both study arms

  5. Values of inflammation parameters - ferritin in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of concentrations of procalcitonin ferritin (μg/l) in peripheral blood in both study arms

  6. Values of inflammation parameters - IL-1 in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of concentrations of procalcitonin IL-1 (pg/ml) in peripheral blood in both study arms

  7. Values of inflammation parameters - IL-6 in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of concentrations of procalcitonin IL-6 (pg/ml) in peripheral blood in both study arms

  8. Values of inflammation parameters - IL-10 in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of concentrations of procalcitonin IL-10 (pg/ml) in peripheral blood in both study arms

  9. Values of inflammation parameters - TNF-alpha in peripheral blood in both study arms

    Time frame: up to 6 months

    Measurement and comparison of concentrations of procalcitonin TNF-alpha (pg/ml) in peripheral blood in both study arms

Secondary outcomes

  1. Correlation between the concentration of TSH (mIU/l) and the parameters of inflammation - leukocytosis in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: leukocyte count (n/µL)

  2. Correlation between the concentration of TSH (mIU/l) and the parameters of inflammation - CRP in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: CRP (mg/l)

  3. Correlation between the concentration of TSH (mIU/l) and the parameters of inflammation - procalcitonin in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: procalcitonin (μg/l)

  4. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: fibrinogen (μg/l)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: fibrinogen (g/l)

  5. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: ferritin (μg/l)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: ferritin (μg/l)

  6. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: il-1

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: iL-1 (pg/ml)

  7. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: il-6

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: iL-6 (pg/ml)

  8. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: il-10

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: iL-10 (pg/ml)

  9. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: TNF-alpha

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: TNF-alpha (pg/ml)

  10. Correlation between the concentration of a-TPO (IU/ml) and the parameters of inflammation - leukocytosis in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: leukocyte count (n/µL)

  11. Correlation between the concentration of a-TPO (IU/ml) and the parameters of inflammation - CRP in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: CRP (mg/l)

  12. Correlation between the concentration of a-TPO (IU/ml) and the parameters of inflammation - procalcitonin in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: procalcitonin (μg/l)

  13. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: fibrinogen (μg/l)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: fibrinogen (μg/l)

  14. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: ferritin (μg/l)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: ferritin (μg/l)

  15. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-1 (pg/ml)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-1 (pg/ml)

  16. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-6 (pg/ml)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-6 (pg/ml)

  17. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-10 (pg/ml)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-10 (pg/ml)

  18. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: TNF-alpha (pg/ml)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: TNF -alpha (pg/ml)

  19. Correlation between the concentration of a-TG (IU/ml) and the parameters of inflammation - CRP in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: CRP (mg/l)

  20. Correlation between the concentration of a-TG (IU/ml) and the parameters of inflammation - leukocytosis in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: leukocyte count (n/µL)

  21. Correlation between the concentration of a-TG (IU/ml) and the parameters of inflammation - procalcitonin in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: procalcitonin (μg/l)

  22. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: fibrinogen (μg/l)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: fibrinogen (μg/l)

  23. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-1 (pg/ml)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-1 (pg/ml)

  24. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-6 (pg/ml)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-6 (pg/ml)

  25. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-10 (pg/ml)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-10 (pg/ml)

  26. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: TNF-alpha (pg/ml)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: TNF-alpha (pg/ml)

  27. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: ferritin (μg/l)

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: ferritin (μg/l)

  28. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - leukocytosis in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: leukocyte count (n/µL)

  29. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - CRP in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: CRP (mg/l)

  30. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - procalcitonin in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: procalcitonin (μg/l)

  31. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - fibrinogen in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: fibrinogen (μg/l)

  32. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - ferritin in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: ferritin (μg/l)

  33. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - il-1 in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: il-1 (pg/ml)

  34. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - il-6 in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: il-6 (pg/ml)

  35. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - il-10 in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: il-10 (pg/ml)

  36. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - TNF-alpha in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: TNF-alpha (pg/ml)

  37. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - leukocytosis in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: leukocyte count (n/µL)

  38. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - CRP in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: CRP (mg/l)

  39. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - procalcitonin in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: procalcitonin (μg/l)

  40. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - fibrinogen in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: fibrinogen (μg/l)

  41. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - ferritin in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: ferritin (μg/l)

  42. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - il-1 in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: il-1 (pg/ml)

  43. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - il-6 in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: il-6 (pg/ml)

  44. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - il-10 in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: il-10 (pg/ml)

  45. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - TNF-alpha in both arms of the study

    Time frame: up to 6 months

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters:TNF-alpha (pg/ml)

Sponsors and collaborators

Lead sponsor

Jagiellonian University

Other

Registry information

Official study title

The Influence of Subclinical Hypothyroidism on Chronic Inflammation Activity in Women With Different PCOS Phenotypes

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
May 3, 2023
Registry last updated
Apr 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.